Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.
“Now that we’ve got the smallest Cas molecule, it opens the door to opportunities,” CEO Amber Salzman told BioCentury. Salzman, a GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) vet, was most recently president and CEO of Ohana Biosciences...